A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Rhodes Pharmaceuticals
- 04 Feb 2016 According to ClinicalTrials.gov record, the treatment table has been amended.
- 04 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 04 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.